This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Exonate at Biotrinity 2022

Posted on 26 Apr 2022

Catalysing Growth in the Life Sciences Industry 
Cambridge, 26th-27th April, Exonate’s CEO Dr Catherine Beech and COO Dr Loic Lhuillier are pleased to attend BioTrinity an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry. 
The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions. 
CEO, Dr Catherine Beech and COO,  Dr Loic Lhuillier are available for meetings, contat can be made via Sarah Buchallet 
Exonate Limited 
Sarah Buchallet, Marketing 
Catherine Beech, CEO Tel:  +44 (0) 1223 734710 
About Exonate: 
Exonate are using the mRNA blueprint as a therapeutic formula to instruct cells in how to treat diseases. Leveraging our expertise in the alternative mRNA splicing of Vascular Endothelial Growth Factor (VEGF) we have developed a pipeline of small molecule drugs for the treatment of patients with chronic diseases 
Exonate’s lead compound, formulated to be delivered topically with eye drops, is now in Phase 1 clinical trials for the treatment of centre-involved diabetic macular oedema. The clinical trial is in collaboration with Janssen Pharmaceuticals, Inc., and built upon extensive pre-clinical work supported by previous investments. Having relocated to larger research labs at MediCity we are continuing our pre-clinical mRNA-targeting research focusing on ophthalmology and renal disease.  

Categories related to this article

Insights, Company news